{
  "abstract": "Introduction Evaluating pulmonary involvement in systemic sclerosis (SSc) traditionally relies on pulmonary function tests (PFTs) and high-resolution computed tomography (HRCT). Additionally, patient-reported outcomes like ScleroID offer insights into quality of life, though their alignment with clinical measures and role in comprehensive care are not well-defined..Material and Methods 74 unselected SSc patients were evaluated at baseline. Lung function was assessed using forced vital capacity (FVC), diffusing capacity for carbon monoxide (DLCO),the six-minute walk test (6MWT). To examine the correlation lung fibrosis on HRCT and quality of life, patients were grouped by fibrosis severity: less than 10%, 10-20%, and more than 20%. Disease activity was quantified using SCTC-AI (Scleroderma Clinical Trials Consortium Activity Index ) and EScSG-AI indices (European Scleroderma Study Group Activity Index ), and disease severity was evaluated using the MSS. (Medsger severity score). Patient-perceived disease impact was assessed through the ScleroID questionnaire. Data were analyzed using descriptive statistics, t-tests or Mann-Whitney U tests for continuous variables, chi-square or Fisher’s exact tests for categorical data, and Spearman’s correlation for associations.Results 65% of participants had interstitial lung disease (ILD), with 31% showing 10–20% lung involvement and 23% having more than 20% involvement on HRCT. SSc-ILD patients were more frequently anti-topoisomerase antibody-positive, had diffuse cutaneous involvement (p<0.001) with higher modified Rodnan skin score (mRSS), lower FVC and DLCO values, and elevated SCTC-AI, EScSG-AI, MSS, and ScleroID scores (all p=0.01). SSc-ILD patients scored higher on the ScleroID breathlessness question (p = 0.01), but no significant differences were found between groups in the fatigue or limitations in life choices subdomains. Stratifying patients based on the extent of lung fibrosis, those with 10–20% fibrosis, showed no significant correlations between lung function, activity/severity scores, and ScleroID subdomains. However, in patients with more than 20% lung involvement, the ScleroID fatigue question correlated with reduced FVC (p = 0.03), oxygen desaturation during the six-minute walk test (p = 0.02), Borg dyspnea scores (p = 0.05). Breathlessness was correlated with SCTC-AI (p=0.02) and EScSG-AI scores (p=0.05), while the MSS showed no significant correlations with ScleroID subdomains, irrespective of fibrosis extent.Conclusions SSc-ILD patients bear a heavier disease burden, with breathlessness standing out as defining feature. Notably, the ScleroID appeared to capture the disease impact more effectively only in patients with advanced fibrosis more than 20% lung involvement), suggesting that it may not fully reflect the experiences of all subsets of ILD patients, particularly those with less severe disease.",
  "authors": [
    {
      "affiliations": [
        "Carol Davila University of Medicine and Pharmacu, Bucharest, Romania"
      ],
      "name": "Groseanu Laura"
    },
    {
      "affiliations": [
        "Carol Davila University of Medicine and Pharmacu, Bucharest, Romania",
        "Sfanta Maria Clinical Hospital, Bucharest, Romania"
      ],
      "name": "Nita Cristina"
    },
    {
      "affiliations": [
        "Carol Davila University of Medicine and Pharmacu, Bucharest, Romania",
        "Sfanta Maria Clinical Hospital, Bucharest, Romania"
      ],
      "name": "Boromiz Catalina"
    },
    {
      "affiliations": [
        "Carol Davila University of Medicine and Pharmacu, Bucharest, Romania",
        "Sfanta Maria Clinical Hospital, Bucharest, Romania"
      ],
      "name": "Mardale Denise"
    },
    {
      "affiliations": [
        "Carol Davila University of Medicine and Pharmacu, Bucharest, Romania",
        "Sfanta Maria Clinical Hospital, Bucharest, Romania"
      ],
      "name": "Ilie Cristian"
    },
    {
      "affiliations": [
        "Carol Davila University of Medicine and Pharmacu, Bucharest, Romania",
        "Sfanta Maria Clinical Hospital, Bucharest, Romania"
      ],
      "name": "Mazilu Diana"
    },
    {
      "affiliations": [
        "Carol Davila University of Medicine and Pharmacu, Bucharest, Romania",
        "Sfanta Maria Clinical Hospital, Bucharest, Romania"
      ],
      "name": "Borangiu Andreea"
    },
    {
      "affiliations": [
        "Carol Davila University of Medicine and Pharmacu, Bucharest, Romania",
        "Sfanta Maria Clinical Hospital, Bucharest, Romania"
      ],
      "name": "Abobului Mihai"
    },
    {
      "affiliations": [
        "Carol Davila University of Medicine and Pharmacu, Bucharest, Romania",
        "Sfanta Maria Clinical Hospital, Bucharest, Romania"
      ],
      "name": "Bojinca Violeta"
    },
    {
      "affiliations": [
        "Carol Davila University of Medicine and Pharmacu, Bucharest, Romania",
        "Sfanta Maria Clinical Hospital, Bucharest, Romania"
      ],
      "name": "Opris-Belinski Daniela"
    },
    {
      "affiliations": [
        "Carol Davila University of Medicine and Pharmacu, Bucharest, Romania",
        "Sfanta Maria Clinical Hospital, Bucharest, Romania"
      ],
      "name": "Balanescu Andra"
    }
  ],
  "title": "P.099 The silent clinical impact of systemic sclerosis-associated interstitial lung disease highlights scleroid’s limitations in early fibrosis",
  "uid": "59b12c87-fe75-5d86-94da-54a6e71e8810"
}